Dyne Therapeutics (DYN) Other financing activities (2020 - 2026)

Dyne Therapeutics (DYN) has 7 years of Other financing activities data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 122.96% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 67.11% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 78.29% from the prior year.
• Other financing activities for Q1 2026 stood at $1.3 million, down from $3.4 million in the prior quarter.
• Over the last five years, Other financing activities for DYN reached as high as $18.0 million in Q3 2024 and fell as low as $18000.0 in Q1 2022.
• Historically, Other financing activities has averaged $2.9 million across 5 years, with a median of $764000.0 in 2023.
• Across the five-year window, Other financing activities jumped 3866.74% in 2024 and plunged 94.61% in 2025, its largest moves.
• Year by year, Other financing activities stood at $342000.0 in 2022, then sank by 56.73% to $148000.0 in 2023, then soared by 2356.76% to $3.6 million in 2024, then declined by 7.43% to $3.4 million in 2025, then sank by 61.05% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $1.3 million in Q1 2026, $3.4 million in Q4 2025, and $2.1 million in Q3 2025.